It’s an OTC stock. There is plenty of discussion. But that won’t suddenly cause the NYTimes or CBS to cover them. And they have talked about their plans. But more likely than not, some things they cannot talk about because they are contingent on other events and may involve other parties. Telling shareholders things that they don’t even intend because they cannot disclose contingent other possible events would not just be disingenuous, but it would probably be seen as a lying.
So I think they are certainly playing some cards close to their chest, but we know they have Sawston, we know their plans for developing it, and I would bet there could be contingency plans if they get approved by MHRA, that they would want to happen but can’t. I could be wrong, but I suspect the careful approach to a first regulator could trigger some events that might be very beneficial but also that cannot be said. But I could be wrong.
News 
Market Data 
Discover 
AI
